Navigation Links
Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
Date:2/12/2008

- Presentation of Efficacy and Safety Phase III Results -

LAUSANNE, Switzerland, Feb. 12 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, presented today at the 9th International Symposium on GnRH in Berlin, Germany, the results of a phase III study with its new 6-month formulation of Decapeptyl(R)/Trelstar(R) (triptorelin), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of advanced prostate cancer. These results show similar efficacy and safety to the already marketed 1- and 3-month formulations.

This multicenter, open, non-comparative, phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer, showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < or equal to 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of triptorelin. Furthermore the adverse event profile of the new 6-month formulation of triptorelin is fully comparable to that observed with the 1- and 3-month formulations.

"Our 1- and 3-month formulations of Decapeptyl(R) and Trelstar(R) are used worldwide in the treatment of prostate cancer. However they require one injection every 4 or 12 weeks respectively. The 6-month formulation will improve patient compliance and increase convenience and comfort with the need of only one intramuscular injection every 24 weeks," said Kamel Besseghir, CEO of Debiopharm S.A.

About Decapeptyl(R)/Trelstar(R)

Triptorelin was licensed-in from Tulane University in 1982. Debiopharm developed and submitted a 1- a
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
2. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
5. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
8. Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report
9. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
10. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
11. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Corgenix Medical Corporation (OTC Bulletin ... of diagnostic test kits, and BG Medicine, ... company, announced today a supply agreement whereby ... in enzyme-linked immunosorbent assay (ELISA) microtiter format ... seeking regulatory clearance in the United States ...
(Date:12/14/2009)... Ga., Dec. 14 ... its flagship integrated EHR, Prime Suite ... CCHIT Certified(®) 2011 Ambulatory EHR, additionally certified ... optional Advanced Reporting. Greenway,s Prime Suite ... new 2011 certification designations offered by the ...
(Date:12/14/2009)... SAN FRANCISCO, Dec. 14 Environmental health ... promised announcement about health hazards of bisphenol A ... behavioral changes, reproductive harm and other illnesses, in ... MD, PhD , staff scientist, Natural ... on your doctor for medical advice, FDA must ...
Breaking Medicine Technology:Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 3Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 4Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public 2Oprah Luke Skywalker and Maradona new study investigates how our brains respond to them 13180 1Oprah Luke Skywalker and Maradona new study investigates how our brains respond to them 13180 2Oprah Luke Skywalker and Maradona new study investigates how our brains respond to them 13180 3Free Webinar on Safer Clinical Hand Offs Offered by Compirion Healthcare 13178 1Free Webinar on Safer Clinical Hand Offs Offered by Compirion Healthcare 13178 2Free Webinar on Safer Clinical Hand Offs Offered by Compirion Healthcare 13178 3Even healthy lungs labor at acceptable ozone levels 52620 1Even healthy lungs labor at acceptable ozone levels 52620 2
... 3 Telik, Inc.,(Nasdaq: TELK ) announced it ... TELINTRA(R) (ezatiostat HCl) Tablets at the 49th,annual meeting of ... Saturday, December 8, 2007, from 5:30 to 7:30 pm ... Center in Atlanta. The presentation,(Abstract # 1454, Board # ...
... ... in Treating Hypertension, ... in the discovery and development of novel small,molecule therapeutics, ... ascending dose (MAD) study of its lead internal,product candidate, ...
Other Medicine Technology:Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 2Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 3Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) 4
(Date:12/14/2009)... are higher than generally thought, raising concerns about increased risk for ... California, San Francisco (UCSF) imaging specialists. , ... ... common CT procedures vary widely and are higher than generally thought, ... study led by University of California, San Francisco (UCSF) ...
(Date:12/14/2009)... Calif., Dec. 14 Grubb & Ellis Healthcare REIT ... authorized a daily distribution to stockholders of record as of ... commencing on Jan. 1, 2010 and ending on Feb. 28, ... days in the calendar year and will be equal to ... price of $10.00 per share. These distributions will be ...
(Date:12/14/2009)... men whose disease had been treated, hadn,t spread, study ... appears to reduce the risk of death in male ... began in January 1986, included 668 men who,d been ... colon cancer that had not spread (nonmetastatic cancer). Every ... them about any new cancer and disease diagnoses, as ...
(Date:12/14/2009)... San Diego School of Medicine and Osaka University in ... liver damage, including inflammation, fibrosis and cancer. The findings ... TAK1, works could lead to new insights into the ... appears to be a master regulator of liver function," ... Dean of the UC San Diego School of Medicine. ...
(Date:12/14/2009)... links perceived age to physical, mental functioning , , , ... younger than their age tend to live longer than ... study suggests. , The finding came from research that ... were given physical and cognitive tests and then had ... the photos and indicated the age they perceived the ...
Breaking Medicine News(10 mins):Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Scientists uncover protective mechanism against liver cancer 2Health News:Looking Younger Than Your Age May Mean Longer Life 2
... that positron emission tomography (PET) that uses a ... and ultrasound in predicting a breast tumours response ... of survival. , In research presented today (Tuesday) ... Barcelona, Dr Vinod Ganju reported that when the ...
... the Swedish medical university Karolinska Institutet (KI) and the ... the biochemical mechanism behind the adhesive protein that give ... of how the malaria parasite makes blood vessels become ... the disease, which currently kills some 2 million people ...
... is greater among white women than black women, report finds ... rates continue to decline more than 2 percent annually, a ... better treatments, according to a new American Cancer Society report. ... among black women as among white and Hispanic women. , ...
... million for research to improve health and welfare of ... companion animals and wildlife, ... opportunity for individuals or groups to demonstrate love,for and help animals ... of about 120 animal health studies available,for sponsorship. Animal lovers are ...
... Regarding Disease Management in the Workplace and Treatment in an Emergency; ... to Wear a ... Medical ID, ... today announced results of a,customer survey regarding disease management in the workplace ...
... 25 Can a small-town doctor,with a big idea ... in,the exploding personal health records (PHR) arena? Steven M. ... Burlingham,s book Small,Giants where companies choose to be great ... dermatologist and entrepreneur created,PassportMD. The free, Web-based service is ...
Other Medicine News:Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 2Health News:PET scans can accurately detect a breast tumor's response to chemotherapy 3Health News:How adhesive protein causes malaria 2Health News:Breast Cancer Death Rates Continue to Fall 2Health News:Breast Cancer Death Rates Continue to Fall 3Health News:Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies 2Health News:Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies 3Health News:People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 2Health News:People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 3Health News:People With Chronic Conditions Experience Additional Benefits of Cost Savings by Wearing a Medical ID 4Health News:Small Town Doctor Takes on Giants in Consumer Healthcare 2
Surgical Stainless Steel Child Stylette....
Aluminum Stylette 16....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...
Medicine Products: